Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease

European Journal of Preventive Cardiology

Volumn 13, Issue 5, 2006, Pages 738-744

  Manresa, Josep Maria ^a   Zamora, Alberto ^b   Tomã¡s, Marta ^a   Sentã, Mariano ^a,c   Fitã, Montserrat ^a   Covas, Marãa Isabel ^a   Alcã¡ntara, Mercedes ^a   Latorre, Glãria ^a   Escurriol, Verãnica ^a   Domingues, Sophie ^a   Marrugat, Jaume ^a,d  

^a Institut Municipal d'Investigaciã Mãdica   (Spain)

^b Hospital de Blanes   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

atherosclerosis; cardiovascular risk factors; genetic polymorphism; non classical risk factors

Indexed keywords

ABC TRANSPORTER A1; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GLUCOSE BLOOD LEVEL; HOMOCYSTINURIA; HOMOZYGOTE; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; OXIDATIVE STRESS; POPULATION RESEARCH; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SOUTHERN EUROPE;

EID: 33749011673     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000224484.80349.3f     Document Type: Article

References (42)

1. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, et al Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project population. Lancet 2000; 355: 688–700.
2. Nguyen VH, McLaughlin MA. Coronary artery disease in women: a review of emerging cardiovascular risk factors. Mt Sinai J Med 2002; 69: 338–349.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
4. Hunt SC Nasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams RR. Genetic heritability and common environmental components of resting and stressed blood pressures, lipids and body mass index in Utah pedigrees and twins. Am J Epidemiol 1989; 129: 625–638.
5. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic epidemiologic study of early-onset ischemic heart disease. Circulation 1980; 61: 503–508.
6. Wienke A, Holm NV, Skytthe A, Yashin AI. The heritability of mortality due to heart diseases: a correlated frailty model applied to Danish twins. Twin Res 2001; 4: 266–274.
7. Xiang AH, Azen SP, Buchanan TA, Raffel LJ, Tan S, Cheng LS, et al Heritability of subclinical atherosclerosis in Latino families ascertained through a hypertensive parent. Arterioscler Thromb Vasc Biol 2002; 22: 843–848.
8. Peyser PA, Bielak LF, Chu JS, Turner ST, Ellsworth DL, Boerwinkle E, et al Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation 2002; 106: 304–308.
9. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 2002; 252: 247–254.
10. North KE, MacCluer JW, Devereux RB, Howard BV, Welty TK, Best LG, et al Strong Heart Family Study. Heritability of carotid artery structure and function: the Strong Heart Family Study. Arterioscler Thromb Vasc Biol 2002; 22: 1698–1703.
11. Hunt KJ, Duggirala R, Goring HH, Williams JT, Almasy L, Blangero J, et al Genetic basis of variation in carotid artery plaque in the San Antonio Family Heart Study. Stroke 2002; 33: 2775–2780.
12. Swan L, Birnie DH, Inglis G, Connell JM, Hillis WS. The determination of carotid intima medial thickness in adults – a population-based twin study. Atherosclerosis 2003; 166: 137–141.
13. Fox CS, Polak JF, Chazaro I, Cupples A, Wolf PA, D'Agostino RA, et al Framingham Heart Study. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke 2003; 34: 397–401.
14. Juo SH, Lin HF, Rundek T, Sabala EA, Boden-Albala B, Park N, et al Genetic and environmental contributions to carotid intima-media thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke 2004; 35: 2243–2247.
15. Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001; 141: S49–S57.
16. Ramos R, Solanas P, Cordon F, Rohlfs I, Elosua R, Sala J, et al Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions. Med Clin (Barc) 2003; 121: 521–526.
17. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 2003; 56: 253–261.
18. Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health 1998; 52: 707–715.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
20. Vasankari T, Kujala U, Heinonen O, Kapanen J, Ahotupa M. Measurement of serum lipid peroxidation during exercise using three different methods: diene conjugation, thiobarbituric acid reactive material and fluorescent chromolipids. Clin Chim Acta 1995; 234: 63–69.
21. Sentí M, Bosch M, Aubó C, Elosua R, Masiá R, Marrugat J. Relationship of abdominal adiposity and dyslipemic status in women with a common mutation in the lipoprotein lipase gene. The REGICOR investigators. Atherosclerosis 2000; 150: 135–141.
22. Sentí M, Tomás M, Elosua R, Sala J, Masiá R, Marrugat J. The paraxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol only in postmenopausal women. The REGICOR Study. Clin Chem Lab Med 2002; 40: 677–683.
23. Tomàs-Abadal L, Varas Lorenzo C, Pérez I, Puig T, Balaguer Vintró I. Risk factors and coronary morbimortality in a Mediterranean industrial cohort over 28 years of follow-up. The Manresa Study. Rev Esp Cardiol 2001; 54: 1146–1154.
24. Bertomeu A, Garcia-Vidal O, Farre X, Galobart A, Vázquez M, Laguna JC, et al Preclinical coronary atherosclerosis in a population with low incidence of myocardial infarction: cross sectional autopsy study. BMJ 2003; 327: 591–592.
25. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150: 149–156.
26. Coles KA, Plant AJ, Riley TV, Smith DW, McQuillan BM, Thompson PL. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Am J Cardiol 1999; 84: 825–828.
27. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965.
28. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–242.
29. Cappuccio FP, Bell R, Perry IJ, Gilg J, Ueland PM, Refsum H, et al Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002; 164: 95–102.
30. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001; 154: 150–154.
31. Kain K, Blaxill JM, Catto AJ, Grant PJ, Carter AM. Increased fibrinogen levels among South Asians versus Whites in the United Kingdom are not explained by common polymorphisms. Am J Epidemiol 2002; 156: 174–179.
32. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, et al Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999; 90: 165–172.
33. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20: 703–707.
34. Frohlich J, Lear SA. Old and new risk factors for atherosclerosis and development of treatment. Clin Exp Pharmacol Physiol 2002; 29: 838–842.
35. Morabia A, Cayanis E, Costanza MC, Ross BM, Flaherty MS, Alvin GB, et al Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors. Hum Mol Genet 2003; 12: 2733–2743.
36. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998; 18: 526–534.
37. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003; 23: 637–643.
38. Flavell DM, Jamshidi Y, Hawe E, Pineda TI, Taskinen MR, Frick MH, et al Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105: 1440–1445.
39. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, et al Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28: 59–66.
40. Corella D, Guillen M, Saiz C, Portoles O, Sabater A, Folch J, et al Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. J Lipid Res 2002; 43: 416–427.
41. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565–575.
42. Jackson LA. Description and status of the azithromicin and coronary events study (ACES) J Infect Dis 2000; 181(suppl 3):S379–S381.